Johnson & Johnson’s Invokana has become the only drug in the SGLT2 inhibitor class to be approved by the FDA for treating diabetic kidney disease (DKD) and to reduce the risk of hospitalisation for heart failure in patients with type 2 diabetes and DKD. Based on results of the CREDENCE trial, J&J’s drug reduced the
Eli Lilly has picked up yet another FDA approval for CDK4/6 inhibitor Verzenio – its third in five months – as it tries to chase down Pfizer’s category-leading Ibrance. The US regulator has given the nod to Verzenio for use in combination with an aromatase inhibitor as initial endocrine-based therapy for women with breast cancer
US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications. Physicians will now be able to prescribe the drug for reducing signs and symptoms in patients with adult and paediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and
